Telavancin Observational Use Registry (TOUR)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Telavancin (Primary)
- Indications Bacteraemia; Bone and joint infections; Endocarditis; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
- Focus Therapeutic Use
- Acronyms TOUR
- Sponsors Theravance Biopharma
- 08 Nov 2017 Data from this registry are expected to be published in 2018, according to a Theravance Biopharma, Inc. media release.
- 31 Oct 2017 According to a Theravance Biopharma media release, preliminary new data (n = 90) from this trial were presented at the 2017 CHEST annual meeting.
- 31 Oct 2017 Preliminary new data (n = 90) presented in a Theravance BioPharma media release.